Saving Lydia (medium.com)

Article summary

The article discusses the challenges of treating rare genetic disorders, where each mutation is unique and affects only a few individuals. A new approach involves open-sourcing the treatment process, including costs, contracts, protocols, and data, to facilitate collaboration and accelerate progress. The goal is to develop effective treatments for these rare disorders, which are often neglected by the pharmaceutical industry. The discussion revolves around the complexities of genetic disorders and the potential of new technologies to address them.

Main themes

• rare genetic disorders
• personalized medicine
• open-sourcing treatment
• genetic engineering
• CRISPR technology

What commenters say

• The traditional pharmaceutical approach to treating rare genetic disorders is broken and a new approach is needed to address the complexity of these diseases.
• Open-sourcing the treatment process can facilitate collaboration and accelerate progress in developing effective treatments for rare genetic disorders.
• The use of CRISPR technology and other genetic editing tools holds promise for treating rare genetic disorders, but raises ethical and safety concerns.
• The concept of open-sourcing a human being is misleading and inaccurate, and the focus should be on sharing relevant data and information to advance medical research.
• The decision to pursue treatment for a rare genetic disorder is complex and involves weighing the potential benefits against the potential risks and uncertainties.
• The development of effective treatments for rare genetic disorders requires a fundamental shift in how we approach medical research and drug development.
• The use of terms like 'open-sourcing a baby' is sensationalistic and misleading, and can detract from the seriousness and complexity of the issues being discussed.